---
title: "Lantern Pharma Inc. (LTRN.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/LTRN.US.md"
symbol: "LTRN.US"
name: "Lantern Pharma Inc."
industry: "Biotechnology"
---

# Lantern Pharma Inc. (LTRN.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | US Market |
| Website | [www.lanternpharma.com](https://www.lanternpharma.com) |

## Company Profile

Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for th...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.64 | 232/604 | - | - | - |
| PB | 3.23 | 244/604 | 3.81 | 3.15 | 1.86 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-09T05:00:00.000Z

Total Analysts: **2**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 2 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.61 |
| Highest Target | 26.00 |
| Lowest Target | 15.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/LTRN.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/LTRN.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/LTRN.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.